SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm restarts Penicillin-G manufacturing facility in AP

30 Jun 2025 Evaluate

Aurobindo Pharma’s wholly owned stepdown subsidiary -- Lyfius Pharma has re-started the production at its Penicillin-G manufacturing facility, at Kakinada, Andhra Pradesh (AP), with immediate effect, after receiving the consent to operate (CTO) from Andhra Pradesh from Andhra Pradesh Pollution Control Board (APPCB), on June 29, 2025.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1443.05 20.95 (1.47%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.00
Dr. Reddys Lab 1267.80
Cipla 1355.80
Zydus Lifesciences 1074.30
Lupin 2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: